MENU
+Compare
VRNA
Stock ticker: NASDAQ
AS OF
Jul 21 closing price
Price
$104.90
Change
-$0.00 (-0.00%)
Capitalization
8.93B

VRNA Verona Pharma plc Forecast, Technical & Fundamental Analysis

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs... Show more

VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for VRNA with price predictions
Jul 21, 2025

Aroon Indicator for VRNA shows an upward move is likely

VRNA's Aroon Indicator triggered a bullish signal on July 17, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 210 similar instances where the Aroon Indicator showed a similar pattern. In of the 210 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 09, 2025. You may want to consider a long position or call options on VRNA as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VRNA just turned positive on July 10, 2025. Looking at past instances where VRNA's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRNA advanced for three days, in of 297 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRNA broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (39.370) is normal, around the industry mean (18.131). P/E Ratio (0.000) is within average values for comparable stocks, (58.574). VRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.444). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (72.993) is also within normal values, averaging (274.844).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VRNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

VRNA is expected to report earnings to fall 245.00% to 2 cents per share on July 31

Verona Pharma plc VRNA Stock Earnings Reports
Q2'25
Est.
$0.03
Q1'25
Beat
by $0.05
Q4'24
Beat
by $0.02
Q3'24
Est.
$-0.07
Q2'24
Missed
by $0.06
The last earnings report on April 29 showed earnings per share of -1 cents, beating the estimate of -7 cents. With 2.73M shares outstanding, the current market capitalization sits at 8.93B.
A.I. Advisor
published General Information

General Information

a r&d company for the treatment of allergic rhinitis and other chronic respiratory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3 More London Riverside
Phone
+44 2032834200
Employees
79
Web
https://www.veronapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EVV10.080.04
+0.40%
Eaton Vance Limited
EMCS31.870.13
+0.40%
Xtrackers MSCI EMs Climate Selection ETF
ELD28.090.09
+0.32%
WisdomTree Emerging Markets Lcl Dbt ETF
SMB17.27N/A
N/A
VanEck Short Muni ETF
NBCC27.61N/A
N/A
Neuberger Berman Nxt Gen Cnnctd Cnsm ETF

VRNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with RYTM. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then RYTM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
N/A
RYTM - VRNA
44%
Loosely correlated
-0.64%
ZYME - VRNA
43%
Loosely correlated
+0.49%
IRON - VRNA
41%
Loosely correlated
+2.79%
ARCT - VRNA
41%
Loosely correlated
+2.15%
CRNX - VRNA
41%
Loosely correlated
-0.51%
More